Evidence map›Paper›PMID 41320957›Full record

ArticleACS infectious diseases2025

Humanization of Drug Metabolism in the

A Kenneth MacLeod, Cristina Merino, Sara Viera-Morilla, Laura Frame, Amy Tavendale, Christina Duncan, Liam Ferguson, Erika G Pinto, Frederick R C Simeons, Vanessa Gomez-Jimenez and 6 more

Abstract read
In one paragraph

Article in ACS infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

A Kenneth MacLeodDrug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.ORCID 0000-0001-6328-1178
Cristina MerinoDrug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
Sara Viera-MorillaGlobal Health Medicines R&D, GSK, Tres Cantos, 28760 Madrid, Spain.
Laura FrameDrug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
Amy TavendaleDrug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
Christina DuncanDrug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
Liam FergusonDrug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
Erika G PintoDrug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
Frederick R C SimeonsDrug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
Vanessa Gomez-JimenezGlobal Health Medicines R&D, GSK, Tres Cantos, 28760 Madrid, Spain.
Ana Belén GarcíaGlobal Health Medicines R&D, GSK, Tres Cantos, 28760 Madrid, Spain.
Jennifer RileyDrug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
Yoko ShishikuraDrug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
María Santos Martínez-MartínezGlobal Health Medicines R&D, GSK, Tres Cantos, 28760 Madrid, Spain.
C Roland WolfDivision of Systems Medicine, Jacqui Wood Cancer Centre, School of Medicine, University of Dundee, Ninewells Hospital, Dundee DD2 4GD, U.K.
Kevin D ReadDrug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.ORCID 0000-0002-8536-0130

Funding

Wellcome Trust
6 · The paper itself

Abstract

Resistance to artemisinin-based combination therapies (ACTs) is steadily increasing in malaria-endemic countries, and new medicines to treat this disease are urgently needed. Drug discovery efforts are hindered by species differences in drug metabolism as new chemical entities must survive metabolism by diverse enzymes across multiple species, enabling cures in preclinical disease models before progression to the clinic. Here, we show how the use of a mouse line extensively genetically humanized for enzymes of the cytochrome P450 superfamily and their transcriptional regulators, the "8HUM" line, can circumvent this issue and improve the translational accuracy of data generated. Engraftment of human erythrocytes into 8HUM/Rag2

Indexed as

AntimalarialsDrug DiscoveryMalariaPlasmodium bergheiAnimalsCytochrome P-450 Enzyme SystemDisease Models, AnimalErythrocytesHumansMicePlasmodium falciparumAntimalarialsCytochrome P-450 Enzyme Systemanimal modelsdrug discoverydrug metabolismmalariaPlasmodium berghei

Identifiers

PMID41320957
PMCPMC12706778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.